3-Methyl-4-oxo-3,4-dihydro-benzo[d][1,2,3]triazine-7-carboxylic acid amide

ID: ALA36730

PubChem CID: 11820225

Max Phase: Preclinical

Molecular Formula: C9H8N4O2

Molecular Weight: 204.19

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  Cn1nnc2cc(C(N)=O)ccc2c1=O

Standard InChI:  InChI=1S/C9H8N4O2/c1-13-9(15)6-3-2-5(8(10)14)4-7(6)11-12-13/h2-4H,1H3,(H2,10,14)

Standard InChI Key:  RABSUFBAIBCCMS-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 15 16  0  0  0  0  0  0  0  0999 V2000
    7.3167   -4.0542    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.6042   -5.3000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8875   -4.8792    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3167   -4.8875    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.6042   -3.6417    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.8917   -4.0542    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7500   -3.6500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1750   -5.3000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4625   -4.0625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1750   -3.6417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6000   -6.1250    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.4625   -4.8875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7500   -2.8250    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.0292   -4.0625    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.0292   -5.3000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  4  1  0
  3  6  1  0
  4  1  1  0
  5  1  2  0
  6  5  1  0
  7  9  1  0
  8  3  2  0
  9 10  1  0
 10  6  2  0
 11  2  2  0
 12  9  2  0
 13  7  2  0
 14  7  1  0
 15  4  1  0
  3  2  1  0
 12  8  1  0
M  END

Alternative Forms

Associated Targets(non-human)

TLX-5 (157 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Biocomponents

Calculated Properties

Molecular Weight: 204.19Molecular Weight (Monoisotopic): 204.0647AlogP: -0.57#Rotatable Bonds: 1
Polar Surface Area: 90.87Molecular Species: NEUTRALHBA: 5HBD: 1
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 13.27CX Basic pKa: CX LogP: 0.86CX LogD: 0.86
Aromatic Rings: 2Heavy Atoms: 15QED Weighted: 0.67Np Likeness Score: -1.81

References

1. Clark AS, Deans B, Stevens MF, Tisdale MJ, Wheelhouse RT, Denny BJ, Hartley JA..  (1995)  Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide.,  38  (9): [PMID:7739008] [10.1021/jm00009a010]

Source